Resources
6 Results (showing 1 - 6)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 12/23/2020 (updated 4/4/2024)
This technical package provides evidence of the effectiveness of strategies and approaches for supporting successful planning, design, implementation, and sustainability of syringe services programs (SSPs). It provides a broad framework for new and existing SSPs to ensure needs-based service delivery, reduce harms related to injection drug use, and link participants to services that support their health and wellness.
Posted 10/28/2020 (updated 4/3/2024)
In this year 2 kickoff session, HRSA Project Officers will share reminders and updates about grant deliverables, the Evaluation Team will give updates, and Technical Expert Leads will discuss new and ongoing technical assistance available to Implementation I and MAT-Expansion grantees.
Posted 6/17/2021 (updated 4/2/2024)
Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking.
Objective:To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence
Posted 6/7/2022 (updated 3/27/2024)
This session provided information on program updates and the Year 2 Sustainability template due September 2022.
Posted 6/7/2022 (updated 3/27/2024)
This session began with a discussion of the timeline, PIMS, sustainability plan, and no cost extensions with the Implementation I cohort. The Implementation II cohort joined the discussion and information was provided on sustaining change in communities.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).